Noubar Afeyan’s most consequential biotechnology assignment in 2026 is not forming another company. It is chairing the board of Moderna as a pandemic-sized cost base is forced to meet an endemic-sized revenue base. The board says the company reduced annual operating expenses by about $2.2 billion in 2025, a faster reset than management had promised. That achievement has bought time. It has not answered whether a smaller Moderna can fund enough late-stage programmes to become a diversified pharmaceutical business.
The arithmetic is unforgiving. Moderna generated $1.94 billion of revenue in 2025, down 40 per cent from the previous year, and recorded a net loss of $2.82 billion. Operating expenses fell to $5.02 billion from $7.18 billion, yet the company still consumed cash as demand for its COVID vaccines settled well below pandemic levels. Three approved products provided a commercial base at year-end, but most revenue still came from COVID vaccination.
The first quarter of 2026 showed both progress and pressure. Revenue rose to $389 million, helped by deliveries under international government partnerships, while research and development spending fell 24 per cent and selling, general and administrative costs fell 18 per cent. Moderna nevertheless reported a $1.34 billion quarterly loss, enlarged by a litigation settlement charge. Cash and investments declined to $7.5 billion at 31 March from $8.1 billion three months earlier, and a $950 million settlement payment is expected in the third quarter.
Afeyan is Moderna’s co-founder and non-executive chairman; Chief Executive Stéphane Bancel controls daily execution. That distinction matters, but it does not insulate the chair from the outcome. Pipeline concentration, capital limits, executive incentives and the pace of restructuring are board questions. After years in which scientific possibility justified expansion, Afeyan must now preside over a governance system willing to rank programmes, close options and hold management to cash outcomes.
A board-led reset moves from promise to arithmetic
Moderna’s contraction began before 2026. In July 2025, the company announced a restructuring that would reduce its global workforce by roughly 10 per cent and take headcount below 5,000 by year-end. The plan was tied to a broader effort to lower projected operating expenses through 2027 while sustaining selected mRNA investments. Manufacturing, clinical development and corporate functions all came under pressure as the company adjusted to lower respiratory-vaccine demand.
The savings were substantial rather than cosmetic. Research and development expense fell 31 per cent in 2025, to $3.13 billion, and the 2026 proxy statement described board-approved use of automation and digital systems across manufacturing, human resources, legal and finance. The same filing said directors regularly reviewed vaccine programmes against changing US demand and regulatory conditions. Cost discipline therefore became part of product governance, not a separate administrative exercise.
Deep cuts can create a misleading sense of success. Closing studies and reducing staff improve the near-term expense line quickly; rebuilding regulatory expertise or specialist manufacturing teams takes longer. A board that rewards savings without tracking lost development speed can preserve cash at the expense of the assets meant to replenish it. Moderna needs to disclose enough milestone progress for investors to distinguish productive simplification from deferred work.
The board has a Product and Technology Committee composed of independent directors, while the full board oversees strategy, risk and capital allocation. That structure allows scientific decisions to be challenged outside management. Afeyan’s role is to make the challenge consequential. Every late-stage programme should have an explicit funding envelope, a decision date and evidence thresholds that can survive a disappointing readout elsewhere in the portfolio.
Governance cadence is as important as governance architecture. Seasonal vaccine sales make quarterly cash use uneven, and clinical events do not align neatly with reporting periods. Directors should therefore test the portfolio under several demand cases: a weaker US vaccination season, a delayed approval, slower international uptake and an oncology trial requiring more patients. A plan that works only at management’s central forecast is not capital discipline.
The pipeline has become a financing hierarchy
Moderna’s strategy places infectious-disease vaccines at the front of a financing chain. Spikevax, the newer COVID vaccine mNEXSPIKE and the RSV vaccine mRESVIA were its three commercial products at the end of 2025. In Europe, approvals in 2026 expanded that base to include mCOMBRIAX, a combined flu and COVID vaccine, while filings for a stand-alone flu vaccine were under review in several markets. Management is targeting revenue growth of as much as 10 per cent in 2026.
The intended logic is that a larger seasonal franchise generates cash for oncology and rare-disease medicines. It is financially coherent, but dependent on several links holding at once. Regulatory clearance must arrive in time for contracting seasons; recommendations must support use in target populations; manufacturing must match local requirements; and products must win against established competitors. Revenue from a vaccine approval can be delayed by a full season if any part of that sequence slips.
Oncology carries the largest opportunity and some of the highest execution risk. Moderna and Merck are testing intismeran autogene across multiple tumour types, with pivotal melanoma data potentially due in 2026. Moderna also initiated a Phase 3 study in high-risk Stage 1 non-small cell lung cancer. The personalised product could diversify the company beyond respiratory demand, but patient-specific manufacturing, turnaround time and combination economics must work at commercial scale.
Rare disease offers a different route. Moderna reached target enrolment in a registrational study for propionic acidemia and entered a collaboration with Recordati to help complete development and, if approved, commercialise the treatment globally. Partnering can distribute spending and add specialist market capability. It can also reduce Moderna’s share of future economics. The board must compare the value of conserved cash with the value surrendered, rather than treating any external financing as an automatic victory.
These franchises cannot all be financed as though success were equally likely. A respiratory product approaching approval, an oncology study awaiting pivotal evidence and an early programme have different risk-adjusted claims on capital. Afeyan should insist that management publishes a stable hierarchy and explains changes. Portfolio flexibility is useful; repeated reprioritisation without decision rules makes it difficult to judge whether science or liquidity is driving the choice.
Cash is ample, but the slope matters
Moderna’s balance sheet remains stronger than that of most loss-making biotechnology companies. Yet the direction and composition of liquidity deserve scrutiny. The $8.1 billion held at the end of 2025 included $600 million drawn from a term-loan facility. By the end of 2026, management expects cash and investments of $4.5 billion to $5.0 billion, excluding any further use of the remaining credit capacity. That range implies another material reduction even after cost cuts.
Runway cannot be judged by dividing the current balance by one quarter’s loss. Vaccine receipts are seasonal, litigation distorts the first quarter, working capital moves with government deliveries and trial spending changes around readouts. The board still needs a clear underlying measure of cash use that reconciles these effects. Investors should be able to see what portion funds continuing operations, what portion covers legacy obligations and what portion creates a new commercial asset.
Gross-margin quality is another warning signal. Unused manufacturing capacity, inventory write-downs and purchase commitments have weighed on vaccine economics since the pandemic. The first-quarter settlement charge obscured improvement in underlying cost of sales, but legal expense does not make the capacity issue disappear. The global network must earn an acceptable return at normal demand, not only provide strategic readiness for an emergency.
A credible capital policy would establish floors rather than rely on broad reassurance. Moderna could define the liquidity needed to fund approved products, complete priority trials and absorb one major delay without emergency financing. Spending above that floor would require stronger evidence or a partner. Such a framework would limit the temptation to preserve every programme until markets, rather than directors, force a decision.
International revenue carries strategic obligations
International markets supplied $311 million, or about 80 per cent, of Moderna’s first-quarter revenue. Deliveries under long-term government partnerships drove much of the increase. The company expects its 2026 revenue to be split roughly evenly between the United States and international markets, making geographic diversification central to the cash plan rather than an optional expansion story.
That shift has required purpose-built manufacturing relationships in Britain, Canada and Australia, along with commercial partnerships in markets including Brazil and Taiwan. Local capacity can strengthen pandemic readiness and reduce supply-chain risk, while government commitments create a degree of demand visibility. It also adds fixed costs, licensing requirements and operational complexity. A facility justified by public-health resilience may not produce the same utilisation or margin as a conventional commercial plant.
Asia-Pacific is therefore a board-level capital question. Australia provides a regional manufacturing base; Taiwan adds a strategically important commercial relationship; and Japanese cohort data support regulatory planning for combination vaccination. These markets have different reimbursement systems, vaccination policies and demographic needs. Moderna cannot assume that a product accepted by one regulator will achieve the same uptake or pricing elsewhere.
Afeyan and the board should assess international sites as a portfolio of contracts, capabilities and contingent obligations. The relevant measures include contracted volumes, local approvals, capacity utilisation, currency exposure and the cost of retaining readiness. Strategic value belongs in the calculation, but it should be stated rather than used to excuse persistently weak economics.
Accountability cannot be outsourced to management
The 2026 proxy statement presents the board as an active participant in cost reduction and portfolio prioritisation. It also highlights a governance tension. The independent compensation committee awarded all named executive officers a 170 per cent overall bonus multiplier for 2025, despite revenue falling short of internal targets, because cost and pipeline performance exceeded other objectives. The award may be defensible, but it raises the standard for proving that the savings protected long-term value rather than simply compensating for weaker sales.
Moderna retains a staggered board, which directors argue provides continuity in a volatile and technically complex period. Continuity can preserve institutional knowledge. It also slows the speed at which shareholders can change board composition. Afeyan has chaired Moderna through its creation, pandemic breakthrough and contraction; that history makes him a valuable strategic memory and an obvious focus of accountability.
The board’s next scorecard should be narrower than the platform ambitions of earlier years. It should measure underlying cash use, on-time regulatory decisions, pivotal evidence, manufacturing utilisation and revenue generated by products beyond the original COVID vaccine. Executive rewards should rise only when those measures improve together. A cost target met by postponing a study or accepting avoidable launch risk is not equivalent to durable productivity.
Moderna has enough liquidity to choose rather than merely react. Afeyan’s test is whether the board uses that advantage before the runway becomes a constraint. If the seasonal franchise can finance oncology and rare disease while the company approaches its year-end cash range, the reset will look like disciplined reinvention. If revenue remains concentrated and late-stage programmes keep drawing on a shrinking balance, the $2.2 billion reduction will have delayed the harder decision instead of resolving it.
